ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 151

Implementation of Recommendations for Prevention of Glucocorticosteroid-Induced Osteoporosis in Hospitalized Patients

Tal Gazitt1, Muna Elias 1, Joy Feld 1, Idit Lavi 1, Amir Haddad 1, Rema Bishara-Garzuzi 1, Muhanad Abu Elhija 1, Adi Kibari 1 and Devy Zisman 2, 1Carmel Hospital, Haifa, Israel, 2Carmel Hospital and Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel, Haifa, Israel

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: glucocorticoids and 25-hydroxyvitamin D, osteoporosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Education Poster

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Glucocorticosteroid-induced osteoporosis (GIO) is the most common cause of secondary osteoporosis but is under-diagnosed and under-treated.  Most professional guidelines recommend as a first step calcium and vitamin D (Ca/VitD) supplementation for patients treated with prednisone ≥ 5-7.5 mg daily or equivalent for ≥ 1-3 months.

Rheumatology inpatient consultations are routinely given by our rheumatology unit with emphasis on smooth transition to outpatient care.  The study objectives were to examine the real-life implementation of recommendations for Ca/VitD supplementation in patients anticipated to receive long-term corticosteroid treatment and to assess the impact of standardized academic lecture on guideline implementation.

Methods: All rheumatology inpatient consultations given in 4 internal medicine wards in an academic community-based hospital in 2018 were included in the study.  The hospital inpatient database was queried by two independent rheumatologists regarding the total number and content of rheumatology consult notes, doses and indications for steroid treatment where applicable, diagnostic codes, and discharge medications including Ca/VitD for patients prescribed ≥ 7.5 mg/day of prednisone with anticipated treatment for ≥ 1 month.  Patients who died during hospitalization and patients hospitalized with diagnostic code of sarcoidosis were excluded from this analysis.    

During the month of July 2018, standardized academic lectures on GIO prevention were given by rheumatologists in 3 of the 4 internal medicine wards.  The fourth internal medicine ward served as control.  The percentage of patients for whom Ca/VitD was both recommended and prescribed and the impact of academic lecture on discharge prescriptions was calculated and compared between the 6-month period before and after the instructional intervention and to the corresponding data in the control internal medicine ward.   Variables were compared by Chi Square test or Student’s t-test, as appropriate.  All tests were 2-sided; p < 0.05 was considered statistically significant.

Results: Rheumatology consultations were given to 559 inpatients in 2018, 101 of whom had steroid treatment and should have been treated with Ca/VitD. The mean age of the patients was 64.6±16.1 years, 59.4% female. The main rheumatologic indications for corticosteroid treatment were vasculitis (26.7%), connective tissue disease (22.8%), rheumatoid arthritis (18.8%), and crystal-induced arthropathy (14.9%). In 79.2% of cases, rheumatology consultations specifically recommended Ca/VitD, but only 44.3% of patients were discharged on supplementation. No statistically significant differences were found among the four wards. GIO prevention lecture had no impact on discharge prescriptions. 

Conclusion: Real-life implementation of GIO prevention guidelines is poor in internal medicine wards.   A collaborative learning program not limited only to academic lectures is recommended as measure of intervention to increase GIO awareness and prevention especially among internal medicine staff.


Disclosure: T. Gazitt, None; M. Elias, None; J. Feld, None; I. Lavi, None; A. Haddad, None; R. Bishara-Garzuzi, None; M. Abu Elhija, None; A. Kibari, None; D. Zisman, Pfizer, 5, 8.

To cite this abstract in AMA style:

Gazitt T, Elias M, Feld J, Lavi I, Haddad A, Bishara-Garzuzi R, Abu Elhija M, Kibari A, Zisman D. Implementation of Recommendations for Prevention of Glucocorticosteroid-Induced Osteoporosis in Hospitalized Patients [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/implementation-of-recommendations-for-prevention-of-glucocorticosteroid-induced-osteoporosis-in-hospitalized-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/implementation-of-recommendations-for-prevention-of-glucocorticosteroid-induced-osteoporosis-in-hospitalized-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology